Resubmitting {formmenu: Zepbound; default=Wegovy; Saxenda; Ozempic; trim=no; name=Medication} {formtext: name=Dose} PA due to the presence of an alternative, FDA-approved diagnosis. Member has a documented history of {formmenu: G47.33 - Obstructive sleep apnea (adult) (pediatric); default=N18.9 - Kidney Disease; I63.9 - Cerebral Infarction (Stroke); trim=no}, which qualifies them for GLP-1 therapy per clinical guidelines. Previous denial was based on {formtext: name=Primary DX}. Documentation has been reviewed and supports this resubmission.